A new intranasal therapeutic vaccine against tuberculosis (TB), developed by researchers at Johns Hopkins University, has been shown in mice to clear bacteria more quickly, reduce lung inflammation, and prevent disease relapse when combined with first-line TB drug therapy. The experimental vaccine, delivered through the nose, targets one of tuberculosis’s most persistent defenses: the bacteria’s […]
